公开(公告)号：WO2019222848A1

公开(公告)日：2019-11-28

申请号：PCT/CA2019/050699

申请日：2019-05-22

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： HAIBE-KAINS, Benjamin ,  CESCON, David

IPC: A61K31/519 ,  A61K31/4184 ,  A61K31/437 ,  A61K31/44 ,  A61K31/4985 ,  A61K31/5025 ,  A61K31/517 ,  A61K31/52 ,  A61K31/55 ,  A61P35/00 ,  C12Q1/6809

Abstract: Provided herein are methods of treating cancers characterized by a high expression of SKA3 gene, such as: breast cancer, prostate cancer, endometrial cancer, ovarian cancer, brain cancer, skin cancer, thyroid cancer, lung cancer, mesothelioma cancer, bladder cancer, colorectal cancer, liver cancer, melanoma, glioblastoma, leukemia or lymphoma, comprising administering a therapeutically effective amount of a TTK inhibitor, such as: CFI-402257, BAY 1161909, BAY 1217389, AZ-3146, NMS-P715, TC Mpsl 12, reversine, Mpsl-IN-1, Mpsl-IN-2, Mpsl-IN-3, MPS BAY1, MPS BAY2a, MPS BAY2b, MPI-0479605, SP600125, S81694/NMS-P153; BOS172722; NTRC 0060-0; NTRC 1501-0; and a pharmaceutically acceptable salt thereof.

公开(公告)号：EP3796914A1

公开(公告)日：2021-03-31

申请号：EP19808414.7

申请日：2019-05-22

Applicant: University Health Network

Inventor： HAIBE-KAINS, Benjamin ,  CESCON, David

IPC: A61K31/519 ,  A61K31/4184 ,  A61K31/437 ,  A61K31/44 ,  A61K31/4985 ,  A61K31/5025 ,  A61K31/517 ,  A61K31/52 ,  A61K31/55 ,  A61P35/00 ,  C12Q1/6809